1. 方法論と範囲
1.1. 調査方法
1.2. 調査目的と調査範囲
2. 定義と概要
3. エグゼクティブ・サマリー
3.1. 製品タイプ別スニペット
3.2. 用途別スニペット
3.3. 販売チャネル別スニペット
3.4. 地域別スニペット
4. ダイナミクス
4.1. 影響要因
4.1.1. 推進要因
4.1.1.1. 慢性疾患の増加と高齢化
4.1.2. 阻害要因
4.1.2.1. 高い開発コスト
4.1.3. 機会
4.1.4. 影響分析
5. 産業分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
6. 製品タイプ別
6.1. 製品紹介
6.1.1. 製品タイプ別市場規模分析および前年比成長率分析(%)
6.1.2. 市場魅力度指数（製品タイプ別
6.2. 栄養補助食品
6.2.1. 序論
6.2.2. 市場規模分析と前年比成長率分析(%)
6.2.3. NMN（ニコチンアミドモノヌクレオチド）
6.2.4. PQQ（ピロロキノリンキノン）
6.2.5. アピゲニン
6.2.6. L-トリプトファン
6.2.7. その他
6.3. その他
7. 用途別
7.1. 導入
7.1.1. 市場規模分析および前年比成長率分析（%）, アプリケーション別
7.1.2. 市場魅力度指数：用途別
7.2. 老化抑制
7.2.1. 序論
7.2.2. 市場規模分析と前年比成長率分析(%)
7.3. 心血管疾患
7.4. 癌
7.5. その他
8. 流通チャネル別
8.1. 流通経路
8.1.1. 市場規模分析および前年比成長率分析（％）、流通チャネル別
8.1.2. 市場魅力度指数（流通チャネル別
8.2. 薬局*市場
8.2.1. はじめに
8.2.2. 市場規模分析と前年比成長率分析(%)
8.3. オンライン
8.4. 小売店
9. 地域別
9.1. はじめに
9.1.1. 地域別市場規模分析および前年比成長率分析(%)
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. 序論
9.2.2. 主な地域別ダイナミクス
9.2.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
9.2.4. 市場規模分析およびYoY成長率分析（%）, アプリケーション別
9.2.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.2.6. 市場規模分析および前年比成長率分析（%）, 国別
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主な地域別動向
9.3.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
9.3.4. 市場規模分析および前年比成長率分析（%）, アプリケーション別
9.3.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.3.6. 市場規模分析および前年比成長率分析（%）, 国別
9.3.6.1. ドイツ
9.3.6.2. イギリス
9.3.6.3. フランス
9.3.6.4. スペイン
9.3.6.5. イタリア
9.3.6.6. その他のヨーロッパ
9.4. 南米
9.4.1. はじめに
9.4.2. 地域別主要市場
9.4.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
9.4.4. 市場規模分析および前年比成長率分析 (%)、用途別
9.4.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.4.6. 市場規模分析および前年比成長率分析（%）, 国別
9.4.6.1. ブラジル
9.4.6.2. アルゼンチン
9.4.6.3. その他の南米諸国
9.5. アジア太平洋
9.5.1. はじめに
9.5.2. 主な地域別ダイナミクス
9.5.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
9.5.4. 市場規模分析および前年比成長率分析（%）, アプリケーション別
9.5.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
9.5.6. 市場規模分析および前年比成長率分析（%）, 国別
9.5.6.1. 中国
9.5.6.2. インド
9.5.6.3. 日本
9.5.6.4. 韓国
9.5.6.5. その他のアジア太平洋地域
9.6. 中東・アフリカ
9.6.1. 序論
9.6.2. 主な地域別ダイナミクス
9.6.3. 市場規模分析および前年比成長率分析（%）, 製品タイプ別
9.6.4. 市場規模分析およびYoY成長率分析（%）, アプリケーション別
9.6.5. 市場規模分析および前年比成長率分析（%）, 流通チャネル別
10. 競合情勢
10.1. 競争シナリオ
10.2. 市場ポジショニング／シェア分析
10.3. M&A分析
11. 企業プロフィール
11.1. Decode Age*
11.1.1. 会社概要
11.1.2. 製品ポートフォリオと説明
11.1.3. 財務概要
11.1.4. 主な展開
11.2. Zeroharm
11.3. Gataca
11.4. Longevity By Nature
11.5. ProHealth, Inc.
11.6. Xandro Lab.
11.7. NanoSPACE
11.8. AgeX Therapeutics, Inc.
11.9. T.A. SCIENCES
11.10. Elysium Health, Inc. (*リストは除外)
12. 付録
12.1. 会社概要とサービス
12.2. お問い合わせ
The Global Anti Senescence Therapeutics Market reached US$ 33.4billion in 2023 and is expected to reach US$ 55.2 billion by 2031 growing with a CAGR of 6.5% during the forecast period 2024-2031.
Anti-senescence therapeutics refer to a category of medical interventions aimed at delaying or reversing the biological processes associated with aging, particularly cellular senescence. Cellular senescence is characterized by the gradual deterioration of cellular function and increased resistance to apoptosis (programmed cell death), which contributes to age-related diseases. The goal of these therapies is to enhance longevity and improve health span the period of life spent in good health by targeting the underlying mechanisms of aging.
This process is marked by a permanent halt in cell division, often triggered by factors such as DNA damage, oxidative stress, or telomere shortening. Senescent cells can secrete inflammatory factors that disrupt tissue function and promote further aging.
Market Dynamics: Drivers
Rising prevalence of chronic diseases and the aging population
The increasing prevalence of chronic diseases linked to aging, including cardiovascular diseases, neurodegenerative disorders, cancer, and metabolic disorders, is a major factor propelling the growth of the anti-senescence therapeutics market. As the global population continues to age, the occurrence of these age-related conditions rises.
As per WHO data in October 2022, the increase in the number of individuals aged 65 and older, which is expected to double by 2050 to around 1.5 billion, the rising number of aging population and age-related diseases that would propel will the demand for the anti-senescence therapeutics market. The growing awareness among the aging population regarding the significance of preventive healthcare will drive the demand for supplements, medications, and lifestyle changes designed to enhance longevity and avert age-related illnesses.
Moreover, key players' strategies such as mergers & acquisitions, and government initiatives such as investments would propel this market growth. For instance, in January 2024, Healthy Extracts Inc. is a platform dedicated to acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals targeting high-growth sectors within the multibillion-dollar nutraceuticals market. The company has introduced LONGEVITY Anti-Aging, a proprietary formulation aimed at promoting skin vitality, enhancing arterial flexibility, and supporting cellular and joint health.
Similarly, in November 2023, Saudi Arabia's Hevolution Foundation, a major initiative dedicated to combating aging, announced $40 million in research grants after the inaugural Global Healthspan Summit. This substantial funding is aimed at catalyzing groundbreaking discoveries in the field of aging science.
A key component of the announcement is a $21 million multi-year partnership with the Buck Institute for Research on Aging, a renowned independent biomedical research institute. This collaboration is specifically focused on accelerating the development of therapeutic interventions that target the fundamental mechanisms of aging.
Restraints
Factors such as high development costs, lack of skilled professionals, regulatory challenges, ethical considerations, and limited clinical evidence are expected to hamper the market.
Market
Segment Analysis
The global anti-senescence therapeutics market is segmented based on product type, application, distribution channels, and region.
The dietary supplements segment accounted for approximately 76.4% of the global anti-senescence therapeutics market share
The dietary supplements segment is expected to hold the largest market share over the forecast period. Dietary supplements aimed at promoting cellular health and mitigating the effects of aging are crucial to the anti-senescence therapeutics market. These products are specifically designed to improve cellular function and resilience, targeting the biological mechanisms that lead to aging.
Moreover, key players in the industry more focus on research studies and introducing innovative products that would propel this segment growth in the market. For instance, major players introduced the One A Day Age Factor Cell Defense, and similar dietary supplements rely on extensive scientific research to validate their ability to support cellular health. These products often contain ingredients like olive polyphenols, which have been shown to combat oxidative stress, a major factor in cellular aging. Studies indicate that olive polyphenols can positively influence biomarkers associated with aging, suggesting their potential to promote longevity.
Also, in June 2024, One A Day, a well-established multivitamin and supplement brand with over 80 years of experience in nutritional science, has recently launched a new product called One A Day Age Factor Cell Defense. This dietary supplement is designed to support cellular health, which is where the aging process begins.
Market Geographical Share
North America accounted for approximately 44.2% of the global anti-senescence therapeutics market share
North America region is expected to hold the largest market share over the forecast period owing to the increasing occurrence of chronic conditions such as cardiovascular diseases, diabetes, and neurodegenerative disorders significantly drive the anti-senescence therapeutics market. The a need for effective treatments that address health issues related to aging. Since these diseases are frequently associated with the aging process, there is a rising demand for therapies that can alleviate their impact and enhance overall quality of life.
North America is experiencing a notable and increasing aging population, with forecasts suggesting that individuals aged 65 and older will represent a larger proportion of the population in the upcoming decades. This demographic change is fueling the demand for anti-aging products and therapies designed to enhance longevity and support healthier aging.
Moreover, in this region, a major number of key players' presence, well-advanced healthcare infrastructure, rising demand for anti-aging and growth in R&D activities, and government investments in healthcare would prople this market growth. For instance, in January 2023, Seragon Biosciences, Inc. launched RESTORIN, an advanced nutraceutical designed to promote healthy aging. This product incorporates a variety of patented technologies developed in collaboration with esteemed institutions such as Harvard University, Mayo Clinic, and Scripps Research. RESTORIN aims to enhance levels of nicotinamide adenine dinucleotide (NAD+) in the body and stimulate senolytic activity, which targets and eliminates senescent cells that contribute to the aging process.
Market Segmentation
By Product Type
Dietary Supplements
NMN (Nicotinamide Mononucleotide)
PQQ (Pyrroloquinoline Quinone)
Apigenin
L-Tryptophan
Others
Others
By Application
Senescence Inhibition
Cardiovascular Diseases
Cancer
Others
By Distribution Channel
Pharmacies
Online
Retail Stores
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
The rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market
Competitive Landscape
The major global players in the anti-senescence therapeutics market include Decode Age, Zeroharm, Gataca, Longevity By Nature, ProHealth, Inc., Xandro Lab., NanoSPACE, AgeX Therapeutics, Inc., T.A. SCIENCES, and Elysium Health, Inc. among others.
Key Developments
In July 2024, MDB Capital Holdings, LLC announced a significant collaboration with the Mayo Clinic to develop a small molecule anti-senescence platform. This partnership is formalized through a patent and know-how agreement and is aimed at advancing research in the fields of longevity and the prevention of age-related diseases.
Why Purchase the Report?
To visualize the global anti-senescence therapeutics
Market Segmentation based on product type, application, distribution channels, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of the anti-senescence therapeutics market with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in excel consisting of key products of all the major players.
The global anti-senescence therapeutics market report would provide approximately 62 tables, 52 figures, and 183 pages.
Target Audience 2023
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by Distribution Channels
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Chronic Diseases and the Aging Population
4.1.2. Restraints
4.1.2.1. High Development Costs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Dietary Supplements *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. NMN (Nicotinamide Mononucleotide)
6.2.4. PQQ (Pyrroloquinoline Quinone)
6.2.5. Apigenin
6.2.6. L-Tryptophan
6.2.7. Others
6.3. Others
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Senescence Inhibition *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cardiovascular Diseases
7.4. Cancer
7.5. Others
8. By Distribution Channels
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
8.1.2. Market Attractiveness Index, By Distribution Channels
8.2. Pharmacies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Online
8.4. Retail Stores
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Decode Age*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Zeroharm
11.3. Gataca
11.4. Longevity By Nature
11.5. ProHealth, Inc.
11.6. Xandro Lab.
11.7. NanoSPACE
11.8. AgeX Therapeutics, Inc.
11.9. T.A. SCIENCES
11.10. Elysium Health, Inc. (*LIST NOT EXHAUSTIVE)
12. Appendix
12.1. About Us and Services
12.2. Contact Us
❖ 世界の抗老化治療薬市場に関するよくある質問(FAQ) ❖
・抗老化治療薬の世界市場規模は？
→DataM Intelligence社は2023年の抗老化治療薬の世界市場規模を468億4,000万米ドルと推定しています。
・抗老化治療薬の世界市場予測は？
→DataM Intelligence社は2031年の抗老化治療薬の世界市場規模を552億米ドルと予測しています。
・抗老化治療薬市場の成長率は？
→DataM Intelligence社は抗老化治療薬の世界市場が2024年～2031年に年平均6.5%成長すると予測しています。
・世界の抗老化治療薬市場における主要企業は？
→DataM Intelligence社は「Decode Age, Zeroharm, Gataca, Longevity By Nature, ProHealth, Inc., Xandro Lab., NanoSPACE, AgeX Therapeutics, Inc., T.A. SCIENCES, and Elysium Health, Inc. など ...」をグローバル抗老化治療薬市場の主要企業として認識しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、納品レポートの情報と少し異なる場合があります。
